

**HOUSE COMMITTEE ON**  
**HEALTH AND HUMAN SERVICES**

**March 11, 2005 Hearing Room D**

**9:30 A.M. Tapes 49 - 52**

**MEMBERS PRESENT:           Rep. Billy Dalto, Chair**

**Rep. Tom Butler, Vice-Chair**

**Rep. Carolyn Tomei, Vice-Chair**

**Rep. Deborah Boone**

**Rep. Kevin Cameron**

**Rep. Mitch Greenlick**

**MEMBERS EXCUSED:        Rep. Gordon Anderson**

**STAFF PRESENT:           Sandy Thiele-Cirka, Committee Administrator**

**Pamella Andersen, Committee Assistant**

**MEASURES/ISSUES HEARD:**

**HB 2202 – Public Hearing**

**HB 2480 – Public Hearing**

**These minutes are in compliance with Senate and House Rules. Only text enclosed in quotation marks reports a speaker's exact words. For complete contents, please refer to the tapes.**

**TAPE/#    Speaker                    Comments**

## TAPE 49, A

- 004 Chair Dalto Calls the meeting to order at 9:35 a.m. States the bills related to background checks reviewed at the March 9 meeting will be addressed together in the House General Government Committee. Opens the public hearing on HB 2202.
- 022 Rep. Greenlick Requests the Oregon State Police (OSP) report back to the Health and Human Services Committee on fingerprint record retention.

### **hb 2202 – PUBLIC HEARING**

- 031 Sandy Thiele-Cirka Administrator. Summarizes HB 2202. Notes the Homeless and Runaway Workgroup will be addressing the committee.
- 056 Jean Lasater Member, Oregon Coalition on Homeless and Runaway Youth. Introduces the panel.
- 068 Kris McAlister Homeless Eugene youth. Shares experiences on the streets of Eugene. Relates experiences with various non-profit organizations. Mentions complications of uncovered and no-crossover services. Recommends reconciliation and prevention support for families. Notes schools are inaccessible to homeless youth.
- 105 Galan Phipps Program Director, Looking Glass Station Seven Youth Shelter. Submits and reviews the workgroup report (**exhibit a**), and provides background on the development of the workgroup and its charge. Reviews findings. Discusses family dysfunctions. Outlines risk factors: homelessness, child abuse, drug and alcohol abuse, mental health and developmental disabilities. Mentions dangers of the street. Discusses lack of services to families, the inequities in federal funding for counties, and the focus on intervention rather than prevention. Presents recommendations to address the challenges.
- 279 Amy Shelburne West Salem High School student. Relates personal story of adoption out of abuse and her personal response to abuse. Reviews her experience in HOST, a group home for runaway and homeless youth.
- 325 Lasater Explains HOST is one of seven federally-funded programs in Oregon. Lists various federal funding types. Explains basic center program and provisions. Notes HOST has nine short-term and six transitional-living beds. Details the waiting lists and the mediation approach with families.

- 445 Chair Dalto Asks about capacities at other facilities throughout the state.
- 410 Lasater Notes each program responds individually to their communities.
- 453 Phipps Elaborates on the capacity of Looking Glass in Eugene.

**TAPE 50, A**

- 009 Rep. Tomei Inquires what will happen to these programs when federal funds are eliminated.
- 012 Lasater Explains their dependence on federal funding. Mentions creative funding of New Avenues for Youth, who recently opened a Ben and Jerry's ice cream shop.
- 044 Marcine Hayes Parent. Reports she became involved with the Host program when her son chose unhealthy behaviors. Relates personal story, and the difficulty she had finding answers that worked and the support she needed. Continues testimony.
- 158 Chair Dalto Inquires about effective training she found.
- 149 Hayes Explains she learned specific communication skills.
- 214 Chair Dalto Asks Shelburne about her adoptive home, her siblings, and how she decided to make changes in her life.
- 222 Shelburne Reports her adoptive home was safe and loving, but she was unwilling to receive their love. She has seven siblings, including adopted three sisters. Notes before she entered the HOST program she was stubborn and isolated, and HOST did not allow isolation.
- 273 Chair Dalto Asks McAlister for comparison between Eugene and Portland homeless youth.
- 279 McAlister Responds the homeless numbers have grown and the statistics are dismal. Mentions city planner who is seeking to form committee to address current trends.
- 280 Chair Dalto

Asks how the problem has changed over time, what does existing prevention look like and how the task force collaborated with the Commission on Children and Families on this bill.

- 333 Lasater Reports there are 1.7 million children a year in the US who have experienced a runaway or homeless episode. States running away is a coping behavior for an unhealthy situation. Discusses prevention in terms of community intervention and crisis resolution.
- 432 Pam Patton President, Collation of Advocates for Equal Access for Girls. Submits and reviews written testimony (**exhibit b**) in support of HB 2202. Shares issues particular to young women.

#### **TAPE 49, B**

- 003 Patton Continues testimony. Discusses impact of abuse and coping mechanisms.
- 067 Rep. Boone Asks why runaway abuse cases are not detected by the system.
- 077 Patton Responds most kids don't say they ran away because they were abused, and counties respond differently to such reports.
- 121 Janet Hawkins Community Action Coordinator, Commission on Children, Families & Community of Multnomah County. Submits and reviews written testimony on the Multnomah County redesign plan (**exhibit c**). Mentions the change in funding amounts and sources.
- 199 Rep. Boone Asks about Jaime Oliver's restaurant model and the possibility of similar models being used by the commission.
- 210 Hawkins Responds yes, best practices can be pursued in the planning process.
- 246 Daniel Pitusky Associate Executive Director, New Avenues for Youth. Testifies in support of HB 2202. Submits and reviews written testimony (**Exhibit d**). Gives details of his home, as well as answers previous questions. Notes their home competes with other non-profits for funding, and so had to raise 30 percent of their funds from private sources. They serve youth between the ages of 12 and 21, a percentage of which have been involved in the child welfare system. Explains they run a 24-bed transitional housing program, have emergency beds, and always have a waiting list. Reports a large number of youth are

coming from out of the area to Portland because there aren't services in their communities.

385 Dennis Morrow Executive Director, Janus Youth Programs. Submits and reviews written testimony in support of HB 2202 (**exhibit d**). Explains personal relationship with the child welfare system. Notes past attempts in move a similar bill.

#### **TAPE 50, B**

011 Morrow Continues testimony. Elaborates on Janus' service area, on his own adopted children, the differences in teen school issues compared to the past, and the lack of funding available to older children.

114 Donna Bolt Coordinator, Office of Educational Improvement & Innovation. Submits and reviews written testimony (**exhibit e**). Delineates what the school districts are doing to assist homeless children in completing their education. Notes the necessity of interagency cooperation.

155 Rep. Boone Notes she does not see the Department of Education (DOE) listed as a partner in the bill under Section 1 (2).

164 Phipps Responds that is an oversight, and the DOE should be included. Recommends that change.

171 Peggy Kahan Program Director, Community Action Agency's Home, Youth and Resource Center. Supports HB 2202. Reports Home provides day shelter services for at-risk, street and homeless teens. Notes their program lost significant funding when the state shifted the budget to early intervention.

200 Chair Dalto Requests Rep. Boone work with Jean Lasater on the bill language to prepare it for passage to the floor.

210 Mickey Lansing Executive Director, Oregon Commission on Children and Families. Submits and reviews report (**exhibit f**). Lists the five core agencies that are working together on behalf of children and families.

243 Chair Dalto States the record will be kept open for additional written testimony. Closes the public hearing on HB 2202. Opens the public hearing on HB 2480.

## **hb 2480 – PUBLIC HEARING**

- 257 Lorren Sandt Managing Ambassador, Hepatitis C Caring Ambassadors Program. Submits and reviews written testimony (**exhibit G**). Notes impact of Hepatitis C on prisoners, the possibility of re-infection and the efficacy and costs of treatment. References and reviews her posters (**exhibit h**).
- 346 Rep. Greenlick Questions the costs and side effects of treatment.
- 350 Sandt Responds. Discusses new drug treatments, and future costs based on expanded impact. Notes everyone is at risk, and mentions instances of co-infection of HIV and Hepatitis C and the difficulty treating both.

### **TAPE 51, A**

- 012 Rep. Greenlick Asks if they intend for the bill to disallow the state from limiting medications used, regardless of cost effectiveness. States this would allow pharmaceutical companies to convince doctors to use the more expensive drug and take away the ability of the state to have a preferred drug list.
- 027 Sandt States they wish to keep the drug recommendations open. Elaborates on possibilities and that physicians need to be educated on all options. Notes resistance is also an issue, and there is no drug that works for everyone.
- 075 Debbie Bowers Nurse, Roche Pharmaceuticals. Discusses drug cocktails designed for individual needs and the issue of patient tolerability. Notes the replication rate of the disease which necessitates aggressive, uninterrupted treatment. Distinguishes between the state having the ability to move people toward a cheaper drug or mandate its use.

*NOTE: Rep. Greenlick, Sandt and Bowers dialogued on this issue from TAPE 51, A, 012 to TAPE 51, A, 148.*

- 148 Bowers References and reviews printed slide presentation (**exhibit h**). Notes costs of liver transplants increasing and the relationship to Hepatitis C, injection drug use is the greatest means of transmission, and resistance development when drug therapies are modified. States liver transplants do not eradicate the disease, rather the new liver becomes infected and treatment must continue.

289	Chair Dalto	Asks definition of de-compensated cirrhosis, and how many people progress to requiring a transplant.
290	Bowers	Provides detailed explanation.
318	Sandt	Comments the cost of living with a lifelong chronic systemic disease is a consideration.
334	Rep. Greenlick	Questions what percentage of people successfully completes a therapy regimen.
337	Bowers	Responds the answer is dependent on which clinical trial is being reviewed, with variation from 50-75 percent.
345	Rep. Greenlick	Inquires about prediction models and whether the state should put resources toward those most treatable.
350	Bowers	Responds no. Reports prediction models are driven by genotype and viral loads.
390	Sandt	Comments even treatment for those most resistant reverses the progression of the disease until another therapy is advanced.
405	Rep. Greenlick	Clarifies question as to whether there are models predicting who will stay on therapy.
413	Sandt	Responds the key to staying on therapy is having proper management by a physician team, and there is no predictor of who will respond to drugs. Notes liver function tests are in trial for that purpose.
432	Rep. Tomei	Inquires about Bowers employer.
433	Bowers	Responds she is a clinical nurse with Roche Laboratories. Identifies drugs manufactured by Roche.
444	Rep. Tomei	Questions if the Oregon formulary covers the drugs presently manufactured by Roche, and those coming down the pipeline; and what portion of people on the Oregon Health Plan (OHP) have Hepatitis C.

453 Bowers Responds existing drugs are covered, and newer drugs must be approved. Notes Roche does not capture statistics on Hepatitis C patients in Oregon. Based on the prevalence rate, with the Medicaid population at two percent, an estimate would be approximately 4,000 are infected.

**TAPE 52, A**

002 Rep. Boone Asks if the bill is seeking to be preventive through the freedom to use the most efficacious drug per individual patient.

021 Sandt Confirms yes.

024 Rep. Tomei Inquires if other health plans have formularies similar to the Oregon Health Plan (OHP).

027 Bowers Responds majority of health plans allow all drugs for Hepatitis C. They are requesting to maintain the status quo in Oregon, and carve out the category of Hepatitis C so drugs are allowed in without restrictions.

046 Barney Speight Administrator, Office of Medical Assistance Programs (OMAP), Department of Human Services (DHS). Submits and reviews written testimony in opposition to HB 2480 (**exhibit I**). Reports the bill will prevent them from effectively managing the disease in the fee-for-service population, as it does not preclude formularies by Oregon managed health care organizations, it only limits the state.

096 Chair Dalto Asks how many primary care physicians are not adequately trained to treat Hepatitis C.

109 Rep. Boone Requests confirmation that physicians choose which patients receive treatment.

111 Speight Responds there are guidelines indicating patients that are likely to go through drug therapy to completion.

124 Rep. Boone Asks if the result is that some patients would not receive treatment therapy.

127 Speight Reports yes, if there is high potential they won't complete the drug therapy.



133	Tom Turek	Medical Director, OMAP, DHS. Offers testimony in opposition to HB 2480. Answers there are 3,000 people in the fee-for-service program that have been diagnosed with Hepatitis C. Reports due to side effects, treatment is cost effective only if patients are ready for treatment.
209	Chair Dalto	Requests further clarification on why a physician needs a secondary review to screen for co-morbidities.
221	Turek	Reports due to expectations on primary care physicians, it is helpful for them to have others to assist in the process.
242	Chair Dalto	Questions need for an insurance company to direct physicians.
245	Speight	Compares the intent to the process of commercial managed care companies. Mentions the problematic issue of expecting physicians to know everything for every disease, and the impact on the standard of care. States intent is to use new evidence bases to form and guide treatment.
280	Rep. Greenlick	Asks Speight to comment on the Audit Committee review indicating the money that could be saved if drugs for depression could have been added to the formulary according to advanced approval models, and compare that to this scenario.
299	Speight	States he heard the report and the savings in the mental health area. Formularies are a tool that state agencies use to balance the issue of quality of care and cost. Notes the value of gatekeepers.
356	Tom Holt	Executive Director, Oregon State Pharmacy Association. Submits and reviews written testimony in opposition to HB 2480 ( <b>exhibit j</b> ). Discusses the costs of the limitations in the bill in terms of disallowance of generics. Notes federal law requires states make available any FDA-approved product in their fee-for-service programs.
471	Rep. Boone	Recommends prevention education.
477	Holt	Responds with confirmation.

**The following prepared testimony is submitted for the records without public testimony:**

	Jean Lasater	Letter in support of HB 2202 from Michael Balter, Ph.D. ( <b>exhibit k</b> ).
	Janet Arenz	Written testimony in support of HB 2202 ( <b>exhibit l</b> ).
	Lorren Sandt	Written testimony in support of HB 2480 from Phyllis Beck ( <b>exhibit m</b> ).
500	Chair Dalto	Closes the public hearing on HB 2480. Adjourns the meeting at 12:30 p.m.

### **EXHIBIT SUMMARY**

- A. **HB 2202, Oregon Homeless and Runaway Youth Work Group Report to the Interim Committee on Health and Human Services, Jean Lasater,**
- B. **HB 2202, written testimony, Pam Patton, 2 pp**
- C. **HB 2202, written testimony, Janet Hawkins, 2 pp**
- D. **HB 2202, written testimony, Dennis L. Morrow, 4 pp**
- E. **HB 2202, written testimony, Dona Bolt, 2 pp**
- F. **HB 2202, written testimony, Mickey Lansing, 2 pp**
- G. **HB 2480, written testimony, Lorren Sandt, 3 pp**
- H. **HB 2480, PowerPoint presentation, Debbie, Bowers, 3 pp**
  - I. **HB 2480, written testimony, Barney Speight, 2 pp**
  - J. **HB 2480, written testimony, Tom Holt, 2 pp**

**The following prepared testimony is submitted for the records without public testimony:**

- K. **HB 2202, letter from Michael Balter, Ph.D., Jean Lasater, 1 p**
- L. **HB 2202, written testimony, Janet Arenz, 2 pp**
- M. **HB 2480, written testimony of Phyllis Beck, Lorren Sandt, 5 pp**